Literature DB >> 24139169

Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.

Francesco Casuscelli1, Elena Ardini, Nilla Avanzi, Elena Casale, Giovanni Cervi, Matteo D'Anello, Daniele Donati, Daniela Faiardi, Ronald D Ferguson, Gianpaolo Fogliatto, Arturo Galvani, Aurelio Marsiglio, Danilo G Mirizzi, Marisa Montemartini, Christian Orrenius, Gianluca Papeo, Claudia Piutti, Barbara Salom, Eduard R Felder.   

Abstract

A novel series of PIM inhibitors was derived from a combined effort in natural product-inspired library generation and screening. The novel pyrrolo[1,2-a]pyrazinones initial hits are inhibitors of PIM isoforms with IC50 values in the low micromolar range. The application of a rational optimization strategy, guided by the determination of the crystal structure of the complex in the kinase domain of PIM1 with compound 1, led to the discovery of compound 15a, which is a potent PIM kinases inhibitor exhibiting excellent selectivity against a large panel of kinases, representative of each family. The synthesis, structure-activity relationship studies, and pharmacokinetic data of compounds from this inhibitor class are presented herein. Furthermore, the cellular activities including inhibition of cell growth and modulation of downstream targets are also described.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-cancer agents; Kinase selectivity; Natural product scaffold; PIM kinases; Pyrrolopyrazinone

Mesh:

Substances:

Year:  2013        PMID: 24139169     DOI: 10.1016/j.bmc.2013.09.054

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition.

Authors:  Luca Mologni; Vera Magistroni; Francesco Casuscelli; Marisa Montemartini; Carlo Gambacorti-Passerini
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

2.  PIM-1 Is Overexpressed at a High Frequency in Circulating Tumor Cells from Metastatic Castration-Resistant Prostate Cancer Patients.

Authors:  Athina Markou; Eleni Tzanikou; Areti Strati; Martha Zavridou; Sophia Mastoraki; Evangelos Bournakis; Evi Lianidou
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

3.  Structure-Based Virtual Screening and De Novo Design of PIM1 Inhibitors with Anticancer Activity from Natural Products.

Authors:  Hwangseo Park; Jinwon Jeon; Kewon Kim; Soyeon Choi; Sungwoo Hong
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.